Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Antonio Morreale

Internal Medicine Shelby Township, MI Medical Doctor

NPI 1609868520 CMS profile 26828

50505 Schoenherr Rd, Suite 300, Shelby Township, MI 48315

Open in the dashboard

General payments

$4,567

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$655,412

7 holdings reported · through program year 2025

Through program year 2025, Antonio Morreale of Shelby Township, MI is reported in the CMS Open Payments database as having received $4,567 across 280 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $655,412 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $892 47
2024 General $1,006 54
2023 General $788 50
2022 General $870 59
2021 General $281 16
2020 General $145 11
2019 General $586 43
2025 Ownership $115,748 1
2024 Ownership $105,590 1
2023 Ownership $96,988 1
2022 Ownership $115,674 1
2021 Ownership $149,338 1
2020 Ownership $36,185 1
2019 Ownership $35,889 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Morreale
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Antonio Morreale were reported at $892. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Antonio Morreale Internal Medicine median Middle half National median
2019 $586 $159 $48–$570 $163
2020 $145 $119 $33–$402 $114
2021 $281 $135 $37–$521 $132
2022 $870 $141 $42–$496 $149
2023 $788 $149 $45–$519 $160
2024 $1,006 $154 $47–$537 $164
2025 $892 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $638 48 payments
  2. Novo Nordisk Inc $539 31 payments
  3. Abbott Laboratories $538 24 payments
  4. Lilly USA, LLC $393 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $359 22 payments
  6. Amgen Inc. $357 25 payments
  7. Pfizer Inc. $341 22 payments
  8. AstraZeneca Pharmaceuticals LP $254 15 payments
  9. Exact Sciences Corporation $163 8 payments
  10. Sanofi-Aventis U.S. LLC $123 7 payments
  11. Other $861 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,567 280 payments
Products named General payments · program years 2019–2025
  1. FreeStyle Libre 3 $538 24 payments
  2. UBRELVY $386 29 payments
  3. QULIPTA $288 20 payments
  4. MOUNJARO $256 16 payments
  5. Otezla $228 16 payments
  6. Ozempic $227 14 payments
  7. RYBELSUS $216 13 payments
  8. Repatha $178 13 payments
  9. Wegovy $172 9 payments
  10. FARXIGA $167 10 payments
  11. Other $3,882 249 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 98 drugs

Part D claims

4,184

Median for Internal Medicine: 777

Drug cost

$272,429

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 34 $44,909
Eliquis Apixaban Brand 26 $29,535
Inderal La Propranolol Hcl Brand 12 $25,489
Repatha Syringe Evolocumab Brand 34 $20,717
Januvia Sitagliptin Phosphate Brand 18 $19,530
Myrbetriq Mirabegron Brand 20 $17,476
Mirabegron Er Mirabegron Brand 20 $13,211
Ozempic Semaglutide Brand 13 $12,853
Buprenorphine Generic 38 $9,443
Repatha Sureclick Evolocumab Brand 17 $9,177

The 10 drugs with the highest cost, of 98 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$27,490

Of which drugs: $2,160

Medicare patients

133

Average age 76

Services billed

773

69 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Atrial fibrillation 26%
Chronic kidney disease 24%
Diabetes 23%
Heart failure 22%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $954

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $83
$83 — —
QULIPTA
  • AbbVie, Inc. $79
$79 — —
Wegovy
  • Novo Nordisk Inc $66
$66 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $32
  • Lilly USA, LLC $18
$50 34 —
MOUNJARO
  • Lilly USA, LLC $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record